Key Highlights

● iSpecimen's third-quarter Revenue more than doubled from a year earlier.

● Growth was driven by government orders, including from the CDC.

● The company is carrying out a 1-for-6 reverse stock split.

● The S&P SmallCap 600 had the worst showing of the major indexes.

iSpecimen (NASDAQ:ISPC) reported that its third-quarter revenue more than doubled on orders from government customers including the Centers for Disease Control and Prevention, news that arrived on Thursday, November 19, alongside a reverse stock split.

The results

iSpecimen reported third-quarter results showing revenue more than doubled from a year earlier. The growth was driven by government orders, including orders from the Centers for Disease Control and Prevention.

iSpecimen is also carrying out a 1-for-6 reverse stock split.

What a reverse split does

A Reverse Stock Split combines existing shares into a smaller number of new ones. In a 1-for-6 split, every six shares a holder owns become one share, and the share price is adjusted upward by roughly the same factor. The total value of a shareholder's stake does not change at the moment of the split, because the company's Market Value is simply divided among fewer shares.

Companies typically carry out reverse splits to lift their share price, often to meet an exchange's minimum price requirement for continued listing or to make the stock eligible for investors who avoid very low-priced shares. A reverse split does not by itself change a company's Business or finances.

What iSpecimen does

iSpecimen runs an online marketplace that connects researchers with human biospecimens, such as blood, tissue and other samples, along with associated clinical data. Its customers include drug developers, diagnostic companies and research institutions that need specific types of samples to develop and test new products. On the Supply side, it works with hospitals, labs and biobanks that collect and store samples.

The model aims to make it faster and easier for researchers to find the samples they need, rather than relying on a patchwork of individual supplier relationships. Demand can rise sharply when public health agencies need large volumes of samples for testing, surveillance or research programmes, which helps explain why government and CDC orders can make a big difference to a small company's quarterly revenue.

iSpecimen is a small company, and quarterly revenue swings can be large in either direction depending on the timing of big orders. Investors often look at whether such orders are one-off or likely to recur.

A difficult market

The news landed on a punishing day for stocks. The FT Wilshire 5000, one of the broadest measures of the US Equity market, fell with the market. The S&P 500 lost 147.80 points to 7,175.83 for a sixth straight decline, and the Nasdaq Composite fell 550.69 points to 23,879.20.

Health care was among the weaker S&P 500 sectors. Smaller companies were hit especially hard: the Russell 2000 dropped 59.20 points to 2,655.11, and the S&P SmallCap 600 had the worst showing of the major indexes.

The selling gathered pace after Anthropic (NASDAQ:ANT)'s record initial public offering began trading around midday, opening at $111.50 and fading to $97.17. Economic data were also soft, with the Philadelphia Fed's November Manufacturing index falling to 6.3 from 20.9.

What to watch

For the stock, investors will watch how the stock trades on a post-split basis and whether government demand continues into the next quarter. Any detail on the size and duration of the CDC and other government orders will matter. The company's ability to broaden its customer base beyond public agencies will also be closely followed. For the FT Wilshire 5000, the Federal Reserve's December 8–9 meeting is the next major macro test.